HomeBUSINESS
BUSINESS

Maruho Grabs Global Rights to RaQualia’s Sodium Channel Blocker
(Dec.26.2017)

Japanese dermatology powerhouse Maruho has obtained exclusive worldwide rights to develop, manufacture, and commercialize a selective sodium channel blocker originated by RaQualia Pharma, a Pfizer Japan spinoff, the two companies said on December 25 ...
(LOG IN FOR FULL STORY)

News Calendar